Get the Stockscreener App
1.51
7.93%
-0.13
Pre-market:
2.03
0.52
+34.44%
NanoViricides Inc stock is traded at $1.51, with a volume of 1.10M.
It is down -7.93% in the last 24 hours and up +19.84% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.64
Open:
$1.59
24h Volume:
1.10M
Relative Volume:
3.40
Market Cap:
$34.40M
Revenue:
-
Net Income/Loss:
$-8.32M
P/E Ratio:
-3.1354
EPS:
-0.4816
Net Cash Flow:
$-7.43M
1W Performance:
-5.03%
1M Performance:
+19.84%
6M Performance:
+19.84%
1Y Performance:
-15.64%
1-Day Range:
$1.50
$1.64
1-Week Range:
$1.44
$1.70
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.51 | 37.36M | 0 | -8.32M | -7.43M | -0.4816 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Rare Ebola strain has no treatment; NanoViricides lines up oral NV-387 - Stock Titan
Shelton biotech NanoViricides raises $2M in stock offering - Hartford Business Journal
A. G. P. Maintains Nanoviricides(NNVC.US) With Buy Rating, Maintains Target Price $6 - Moomoo
NanoViricides Highlights NV-387 Strategy for Ebola Outbreak - TipRanks
NanoViricides Completes $2 Million Registered Direct Offering - TipRanks
NanoViricides Raises $2 Million in Registered Direct Offering With Common and Pre-Funded Warrants - TradingView
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides... - Proactive financial news
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug - citybuzz -
NanoViricides closes $2M direct offering - Yahoo! Finance Canada
NNVC stock up 17% today: What’s driving the rally? - MSN
NanoViricides, Inc - Reuters
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering - ACCESS Newswire
Antiviral developer NanoViricides secures $2M from single institutional investor - Stock Titan
NanoViricides Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak - citybuzz -
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak - Yahoo! Finance Canada
New Ebola strain has no treatment — NanoViricides highlights oral NV-387 - Stock Titan
About Us - FinancialContent
NanoViricides Prices $2 Million Registered Direct Offering - citybuzz -
NanoViricides Advances NV-387 Toward Phase II Trials for MPox in DRC, Expands Orphan Drug Strategy - citybuzz -
NanoViricides to raise $2M in registered direct offering - Yahoo! Finance Canada
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering - ACCESS Newswire
Clinical-stage antiviral firm NanoViricides prices $2M stock-and-warrant deal - Stock Titan
NanoViricides, Inc. Has Filed its Quarterly ReportNV-387 Advancing for Phase II - Lelezard
Broad antiviral NV-387 drug candidate targets measles, mpox, smallpox - Stock Titan
NANOVIRICIDES, INC. 3Q FY2026: Net loss $(1.99M), EPS $(0.09) — 10-Q Summary - TradingView
NanoViricides: Fiscal Q3 Earnings Snapshot - marketscreener.com
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
NNVC Stock Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
TradingKey - TradingKey
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship - citybuzz -
Small cap wrap: Gunnison Copper, Graphene Manufacturing Group, NanoViricides… - Proactive financial news
NanoViricides says hantavirus incident highlights need for antiviral drugs - TipRanks
Does the Recent Hantavirus Outbreak Highlight a Critical Gap for NanoViricides' NV-387 - Kavout
NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak - Yahoo Finance
Cruise ship hantavirus deaths spark call for broad-spectrum antiviral drugs - Stock Titan
What NanoViricides (NNVC) bond yields suggest about risk | Q1 2026: Earnings Beat EstimatesCommunity Chart Signals - newser.com
NNVC (NanoViricides) shares surge 9% as EPS beat targets by 23%, defying analyst expectations despite ongoing losses.Spin Off - newser.com
NanoViricides to Present at D. Boral Capital Global Conference as Lead Drug Candidate Advances Toward Phase II Trials - citybuzz -
NanoViricides to Present at D. Boral Capital Global Conference - HarianBasis.co
NanoViricides (NNVC) Secures FDA Orphan Drug Status for NV-387 Measles Treatment - Insider Monkey
NanoViricides to Participate at D. Boral Capital Global Conference in NYC - Yahoo Finance
NanoViricides to present at D. Boral Capital Global Conference May 7 in NYC - Pluang
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference - Oil & Gas 360
NanoViricides to attend D Boral Capital Conference - Proactive financial news
NanoViricides management offers investor meetings in New York May 7 - Stock Titan
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - Yahoo Finance
NanoViricides’ NV-387 Receives FDA Orphan Drug Designation for Measles Treatment - MEXC
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):